Montefiore Investment acquired a majority stake in Demenego from Vam Investments. This secondary LBO follows a highly successful four-year period of ownership by the seller, during which the company more than doubled its revenue and expanded its retail network from 15 to 39 stores. The new partnership is designed to build on this solid foundation, with a strategic focus on further transforming the eyewear specialist into a national leader through innovation and omnichannel development. The investment strategy emphasizes continued significant investment in digitalization, customization technology, and the expansion of the "Demenego Labs" concept. The CEO and management team remain in place to execute this next phase of growth, aiming to capitalize on the firm's reputation for visual healthcare and rapid production capabilities. The transaction highlights the group's position as a high-margin, specialized retail platform in a consolidating European market.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.